Status
Conditions
Treatments
About
DISCLOSE trial is a randomized controlled trial including 532 participants with low-energy distal radius fractures. The primary objective is to evaluate whether casting without prior closed reduction is equivalent to casting following closed reduction with respect to wrist-related pain and disability, as measured by the Patient-Rated Wrist Evaluation (PRWE) score at 12 months, in patients aged 65 years or older with a displaced distal radius fracture.
Full description
Interventions:
No reduction: In the no reduction group, a dorsal cast is applied to the patient's wrist after the initial radiograph. Following casting, a control radiograph will be taken. Active range of motion exercises for the fingers and light use of the hand are recommended immediately.
Closed reduction: Distal radius fracture reduction is performed in the emergency department under local anaesthetic, with lidocaine infiltrated into the fracture site. Closed reduction is performed by the on-call physician who is responsible for the patient's treatment. Post-reduction radiographs are then taken to assess fracture alignment, although the findings do not influence the treatment of the patient. The follow-up visits, cast removal, and exercise protocol are identical to those inof the no reduction group.
In both groups, the cast will be removed after 5 weeks at either the health center or the hospital's outpatient clinic, in accordance with the local treatment protocol. Following cast removal, patients will be advised to resume everyday use of the injured wrist without restrictions. No radiographs will be taken during the casting period or before the 3-month follow-up.
Observational arm (not part of the randomised equivalence trial): Eligible patients who decline participation in the randomisation will be offered the opportunity to join an observational group. The patients will receive standard care (closed reduction and casting) and will provide consent for follow-up. Reduction of the DRF is performed in the emergency department and post-reduction radiographs will be taken. The observational groups will be treated according to local treatment protocols. Patients in the observational cohort will be followed at the same time points using the same outcome measures as the randomised group. Study follow-up of the observational group will be organized remotely.
Blinding: Recruiting will start at July 2025.Due to the nature of the intervention, the participants will not be blinded. Recruiting personnel will only have access to the randomisation module within the electronic REDCap (Research Electronic Data Capture, https://www.project-redcap.org/) software. The outcome assessors (study nurse or orthopaedic resident or specialist) who collect the baseline data and outcome measures from the follow-up visits will be blinded to the randomisation result. Furthermore, the study personnel involved in the follow-up visits will remain blinded to the randomisation results, as the results will be hidden in REDCap.
Follow-up: Participants will meet a research personnel or coordinator study nurse at the 3-month and 12-month time points. At the 3-month time point, radiographs will be taken. Thereafter, no additional radiographic follow-ups will be organized. Follow-up appointments will be carried out according to the preferences of the participants. For example, all patients will be invited to attend an in-person follow-up visit; however, if this is unsuitable, the follow-up will be conducted remotely via telephone or email link by a blinded study nurse. In the remote option, the accelerometer wristbands will be sent to the participants by regular mail. By offering a remote option, we aim to minimise the number of participants unavailable for follow-up. The participants will receive follow-up questionnaires via email or regular mail prior to their follow-up appointment. If they decline to complete the questionnaires, outcomes will be collected via a telephone interview. The research data will be saved in a database using the online patient management program REDCap. The 5-year follow-up will be conducted by phone.
Rehabilitation: All patients presenting with unsettling symptoms will undergo physiotherapy rehabilitation for up to one year, as in standard care. If the symptoms do not improve during this period, the patient will be referred to an orthopaedic surgeon or hand surgeon for further evaluation where necessary procedures, such as a computed tomography (CT) scan and, in some cases corrective osteotomy, will be considered.
Sample size and power considerations: The sample size was determined based on an equivalence design with an equal allocation ratio (1:1). Based on the MID for PRWE of 11.5 points, the equivalence margin was set at 6 points. This represents the maximum acceptable difference in means between the groups to still be able to consider the groups as equivalent. Based on the findings of previous studies, the standard deviation of the outcome (PRWE) variable was estimated to be 21.9. Using these parameter estimates, a total sample size of 532 participants (266 per group) will provide 90% power to demonstrate equivalence between groups on the primary endpoint, assuming a true mean difference of < 0.01, a common standard deviation of 21, and equivalence margins of -6 to 6 on the PRWE score. The calculation was based on a 2-sided 90% confidence interval (α = 0.05) and used the exact method for two-sample means under normal distribution assumptions.
Enrollment
Sex
Ages
Volunteers
Inclusion criteria
Exclusion criteria
Primary purpose
Allocation
Interventional model
Masking
532 participants in 2 patient groups
Loading...
Central trial contact
Laura Kärnä, MD; Ville Ponkilainen, MD, PhD
Data sourced from clinicaltrials.gov
Clinical trials
Research sites
Resources
Legal